GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opus Genetics Inc (STU:R3X1) » Definitions » Float Percentage Of Total Shares Outstanding

Opus Genetics (STU:R3X1) Float Percentage Of Total Shares Outstanding : 95.74% (As of Dec. 15, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Opus Genetics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Opus Genetics's float shares is 30.23 Mil. Opus Genetics's total shares outstanding is 31.57 Mil. Opus Genetics's float percentage of total shares outstanding is 95.74%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Opus Genetics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Opus Genetics's Institutional Ownership is 6.78%.

Opus Genetics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Opus Genetics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=30.23/31.57
=95.74%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Opus Genetics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opus Genetics Inc (STU:R3X1) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
NKGN SPRO CASI XLO ASMB OCEA FIXX CRVS NGM GBIO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
IRD:USA
Address
37000 Grand River Avenue, Suite 120, Farmington Hills, MI, USA, 48335
Website
https://www.opusgtx.com
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Opus Genetics Headlines

No Headlines